Peptide education
Gonadorelin
GnRH · Gonadotropin-releasing hormone · Lutrepulse · Factrel
Gonadorelin is synthetic GnRH, the ten-amino-acid hypothalamic signal that tells the pituitary to release LH and FSH, and it holds something most gray-market peptides lack: a genuine human approval history, including a 1989 orphan approval for pump-driven ovulation induction in women who cannot make their own GnRH. The catch is the word pump. GnRH works in pulses, roughly every 90 minutes, because continuous exposure downregulates its own receptor. The intermittent weekly injections sold by clinics and discussed on forums are a different regimen from the one the evidence describes, and the physiology says the difference is not a detail.
In GnRH-deficient patients on 90-minute pump pulses, gonadorelin genuinely restores reproductive function. Intermittent clinic injections for TRT support borrow that credibility without the schedule that earned it.
Overview
Quick answer
The name shows up in several very different settings: historical human products such as Lutrepulse, specialist pump-based GnRH studies, current U.S. animal-drug labels, men's-health clinic pages, and research-use vendor vials. A cattle label, a historical human pump regimen, and a vendor vial mean different things: animal use, specialist human physiology, and product claims. The strongest human literature usually uses frequent pump pulses, often every 90 minutes, while clinic and online pages often discuss much less physiologic injection schedules.
What is gonadorelin?
Synthetic GnRH, identical to the native decapeptide, with a half-life of about 2 to 4 minutes. It triggers pituitary LH and FSH release, placing it in the reproductive axis, not the growth-hormone secretagogue category that peptide menus often lump it into.
What do people use it for?
The studied uses are diagnostic stimulation testing and pulsatile pump treatment of GnRH-deficient conditions: hypothalamic amenorrhea in women, congenital hypogonadotropic hypogonadism in men. The marketed uses are different: TRT add-on, hCG substitute, testicular-volume support, post-cycle restart, at schedules no published study validates.
What specialist study schedules are reported?
Pump pulses every 90 minutes: 5 to 20 micrograms per pulse in female hypothalamic-amenorrhea regimens, 10 micrograms per pulse with careful titration in male CHH studies, sustained for months. The single 100-microgram injection appears as a diagnostic stimulation test, not a treatment. None of this resembles one to three injections a week.
Why does pulsatile use matter?
Because the receptor demands it: continuous GnRH exposure downregulates its own receptor, so the molecule that restores fertility in pulses can suppress the axis when dripped in steadily. An intermittent clinic shot is neither the pump pattern nor a studied alternative, which helps explain why clinics themselves disagree about whether gonadorelin works as an hCG replacement.
Reported practice
Commonly reported protocol
Community HPTA-restart protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Human records and publications point to a narrow context: historical Lutrepulse use, diagnostic endocrine testing, and specialist reproductive-endocrinology studies where GnRH signaling is deficient.
Current DailyMed results are mostly animal-drug records, including cattle-only Factrel labeling. That is animal-drug context, not evidence for human fertility, testosterone, or wellness use.
Clinic and vendor pages often market gonadorelin around TRT support, hCG substitution, lyophilized research vials, purity claims, and COAs. That explains what appears online, but it is not clinical proof.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Gonadorelin helps ovulation or fertility in GnRH-deficient settings. | This is the most credible therapeutic area. The historical Lutrepulse approval context and registry records point toward specialist reproductive-endocrinology use, especially where GnRH signaling is deficient and pulse timing is central. | GnRH pulses stimulate pituitary LH and FSH release. In the right endocrine setting, that upstream signal can support ovarian follicle development, ovulation, testicular testosterone production, or spermatogenesis. | Online fertility and men's-health discussion often uses this physiology for broader goals. That is where broad online claims can stretch the specialist pump literature too far. | Most credible when the claim stays tied to GnRH deficiency, specialist assessment, and pump-style study regimens. Much weaker when applied to general wellness or broad hormone optimization. |
| Gonadorelin boosts testosterone naturally. | Gonadorelin can increase LH and FSH signaling when the pituitary-gonadal axis can respond. The direct human evidence is specialist endocrine context, not a broad low-testosterone or wellness population. | The mechanism makes the claim understandable: LH can stimulate testicular testosterone production. What matters is schedule, diagnosis, and whether the person has a responsive axis. | Clinic pages and forums commonly talk about gonadorelin as a "natural" testosterone-support peptide or TRT adjunct. That is a common clinic and forum framing, with much weaker direct support than the pump literature. | Plausible biology, but not broad evidence of testosterone optimization. The best-supported context remains specialist reproductive endocrinology. |
| Gonadorelin preserves fertility or testicular size during TRT. | Clinic and compounding-pharmacy marketing commonly presents this theme, but the best-supported published context here involves hypothalamic amenorrhea or male congenital hypogonadotropic hypogonadism, not routine TRT-adjunct use. | LH and FSH are relevant to intratesticular testosterone and sperm production, so the biology is relevant. The schedule mismatch matters because GnRH physiology is pulse-dependent. | Men's-health clinics, pharmacies, and online users discuss gonadorelin as an hCG alternative after hCG compounding changed. Clinics also disagree about whether gonadorelin works well for that role. Intermittent clinic injections have a different exposure pattern than physiologic pump pulses, so that schedule needs its own evidence. | Commonly discussed, but the pump literature is a poor match for intermittent TRT-adjunct schedules. |
| Gonadorelin is basically hCG. | hCG and gonadorelin can both affect reproductive hormones, but they act at different points in the axis. Gonadorelin stimulates pituitary GnRH receptors; hCG acts more like an LH signal at the gonads. | GnRH pulse timing, pituitary responsiveness, gonadal responsiveness, and existing sex-steroid suppression all change the expected result. That is why a simple equivalence claim is too broad. | Clinic and pharmacy pages often use hCG-replacement language, especially after compounding changes affected hCG access. | Related conversation, different pharmacology. Treating gonadorelin as a drop-in hCG replacement overstates the current evidence. |
| Gonadorelin is a GH secretagogue, fat-loss, muscle-gain, or anti-aging peptide. | The cited human gonadorelin sources are about GnRH signaling, diagnostic testing, and specialist reproductive-endocrinology care. They are not growth-hormone, body-composition, muscle-gain, or anti-aging evidence. | Gonadorelin is part of the GnRH/LH/FSH reproductive axis. GH secretagogues and GHRH analogs work through different hormone systems. | Peptide-market pages sometimes group many injectables together. That can blur categories and make gonadorelin sound like a general optimization peptide rather than a reproductive-axis drug. | Wrong category for GH claims, and weak support for fat-loss, muscle, or anti-aging claims. |
Bottom line
Main takeaway
Gonadorelin is GnRH: a legitimate reproductive-endocrinology drug for specific GnRH-deficiency problems, not a general hormone-optimization peptide.
Ask which gonadorelin is being discussed: the historical Lutrepulse pump, a diagnostic test, a cattle-only veterinary label (most of the current U.S. labels), a clinic add-on, or a research-use vial. Same molecule, completely different evidence and oversight.
Anchor on the 1989 Lutrepulse orphan approval, the ClinicalTrials.gov pulsatile-GnRH registries, and the 1980s diagnostic literature. Read clinic and vendor material as a separate, weaker source class with an unresolved schedule problem.
Identity
What it is
Gonadorelin is the synthetic form of endogenous GnRH, also called LHRH: a decapeptide that signals the pituitary to release LH and FSH, which then act on the ovaries or testes. Its half-life is about 2 to 4 minutes, identical to the native hormone.
The pulse biology is the whole mechanism. Natural GnRH arrives in bursts, and the pituitary reads that rhythm; continuous exposure flips the effect and downregulates the receptor. That is why the core fertility literature is built on pumps firing every 90 minutes, and why "the same molecule" on a weekly clinic schedule is not the same treatment.
The market conversation loses this thread. The best evidence sits in specialist GnRH-deficiency care and diagnostic testing; the visible U.S. labels are now mostly veterinary, including cattle-only Factrel; and the clinic demand is TRT support and hCG replacement, a role that grew after hCG compounding changed and that the pump literature simply does not address.
How people talk about it online
Men's-health clinics and compounding pharmacies present gonadorelin as a TRT companion, a fertility-preservation tool, or an hCG alternative. Those pages explain the demand, and some clinics openly doubt the hCG-substitute role, which tells you the practice outran the evidence.
Forums argue the practical questions: whether gonadorelin keeps testes active during TRT, whether it feels weaker than hCG, whether 100 to 200 micrograms one to three times weekly for 4 to 8 weeks does anything. That post-cycle pattern is anecdote-level, and everyone in the thread senses the schedule problem even when they cannot name it.
Vendor listings offer 2 mg and 5 mg research-use vials with HPLC-MS, purity, and COA language. None of that paperwork settles sterility, endotoxin, stability, or chain of custody for an injectable.
Use context
Routes, doses, and cycle patterns
The practical distinction is pulsatile pump use versus intermittent injection discussion. The best-supported human regimens are designed to imitate natural GnRH pulses. Current clinic, forum, and vendor conversations often shift the goal toward TRT support or hormone optimization and use occasional injection schedules that cannot be judged by pump-based pulse replacement alone.
Human studies and product labels
Historical Lutrepulse human context
- Purpose
- Ovulation induction in hypothalamic amenorrhea due to deficient GnRH secretion
- Context
- Historical FDA orphan approval context
- Route
- Pump-based delivery in historical product and study discussions
- Amount
- Historical and registry-linked GnRH pump regimens use microgram-range pulses under specialist supervision; those pulses are not intermittent clinic-injection schedules
- Frequency
- Specialist pump regimens are often described around every-90-minute pulses
- Duration
- Duration varies by specialist care plan and is not a general-use cycle
This human product context is historical and condition-specific. Modern wellness, TRT, and vendor-vial use need their own evidence.
ClinicalTrials.gov LutrePulse study
- Purpose
- Hypogonadotropic hypogonadism / primary amenorrhea research context
- Context
- ClinicalTrials.gov registry
- Route
- Subcutaneous pump delivery
- Amount
- Registry-linked LutrePulse materials describe 10, 15, or 20 micrograms per pulse
- Frequency
- Every 90 minutes in the registry-linked study materials
- Duration
- Duration varies by study design and is not a reusable general-use cycle
This pattern illustrates how different specialist GnRH treatment is from intermittent peptide-market injection schedules.
Male hypogonadotropic hypogonadism pump studies
- Purpose
- Puberty, testosterone, testicular volume, or spermatogenesis outcomes in male CHH
- Context
- Specialist clinical literature in male CHH
- Route
- Subcutaneous pulsatile pump
- Amount
- Some male CHH pump regimens start at 10 micrograms per pulse, with 5 microgram upward titration in some studies
- Frequency
- Every 90 minutes in the male CHH pump examples discussed here
- Duration
- Months-long to longer specialist follow-up, depending on study design
The male CHH literature describes meaningful endocrine and fertility outcomes, but those results came from specialist pump treatment, not intermittent clinic add-on injections.
Historical diagnostic testing
- Purpose
- Pituitary-gonadal-axis response testing
- Context
- PubMed diagnostic paper and historical diagnostic literature
- Route
- Intravenous or subcutaneous in historical diagnostic contexts
- Amount
- Historical diagnostic examples include 100 microgram gonadorelin stimulation testing
- Frequency
- Single stimulation test in diagnostic contexts
- Duration
- Short testing window with timed blood sampling in diagnostic studies
Diagnostic stimulation testing is different from chronic fertility treatment or TRT-adjunct marketing.
Real-world discussion
Community HPTA-restart protocols
- Purpose
- Post-cycle and fertility discussion
- Context
- Forums, clinics, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Community schedules typically describe 100 to 200 mcg per administration, one to three times weekly, framed around restoring pulsatile GnRH signaling.
- Frequency
- One to three times weekly in most descriptions
- Duration
- Typically 4 to 8 week runs
Gonadorelin is a prescription diagnostic form of GnRH, and its physiology is genuinely pulsatile, which is why community sources argue against continuous schedules. Human evidence for the post-cycle framing is anecdote-level. Reported as context, not a recommendation.
What varies
- Goal: ovulation induction, male CHH fertility, diagnostic testing, TRT support, and generic wellness claims require different evidence.
- Schedule: every-90-minute pump pulses try to imitate GnRH physiology; occasional clinic injections may produce a different LH/FSH pattern.
- Axis status: gonadorelin depends on pituitary and gonadal responsiveness; it is not a direct sex-steroid replacement.
- Product type: historical human products, registry drugs, veterinary labels, compounded products, and research-use vials differ in oversight, intended species, route controls, and evidence.
- Quality: for injectables, identity and purity claims do not settle sterility, endotoxin, concentration, storage, or chain of custody.
Human data
Human evidence
The human evidence is genuine and narrow. Historical approval records, ClinicalTrials.gov registries, and diagnostic literature support gonadorelin as a pulsatile specialist treatment and a stimulation-test agent in defined reproductive-endocrine settings, with the strongest regimens delivered by pump every 90 minutes for months in GnRH-deficient women and men with congenital hypogonadotropic hypogonadism. Current U.S. label visibility is mostly veterinary. The intermittent TRT-adjunct schedules common in clinics and forums sit outside everything the published record tested.
Evidence maturity
Gonadorelin has genuine historical human evidence in narrow specialist settings, but current U.S. labels are mostly veterinary and common clinic uses sit outside the studied regimens.
Established in the 1980s as a human endocrine stimulation-test agent for pituitary LH and FSH response.
Lutrepulse received orphan approval in 1989 for pulsatile pump ovulation induction in GnRH-deficient women.
Every-90-minute pump regimens produced endocrine and fertility outcomes in male congenital hypogonadotropic hypogonadism research.
Today's U.S. DailyMed visibility is mostly animal-drug labels, including cattle-only Factrel, while human use persists in specialist research.
Clinic TRT-adjunct and vendor use relies on intermittent injection schedules the pump-based evidence does not cover.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Historical Lutrepulse approval context | Women with hypothalamic amenorrhea due to deficient endogenous GnRH secretion | Historical FDA orphan approval context | Historical human product | Supports a real human therapeutic context for gonadorelin, especially when described as specialist reproductive-endocrinology treatment rather than broad peptide-market use. | Historical product context leaves current U.S. human availability and modern clinic, TRT, or gray-market schedules unanswered. | Moderate |
| LutrePulse ClinicalTrials.gov registry | Specialist reproductive-endocrinology patients with hypogonadotropic hypogonadism or primary amenorrhea | ClinicalTrials.gov registry | Investigational or specialist product context | Shows continuing specialist use of gonadorelin/GnRH pump treatment in defined reproductive-endocrinology populations. | Registry context is not a general-use regimen and does not verify compounded or research-use products. | Limited-human |
| Pulsatile GnRH registry context | Male idiopathic hypogonadotropic hypogonadism research context | ClinicalTrials.gov registry | Specialist research context | Supports the idea that gonadorelin remains relevant to specialist male reproductive-endocrinology research. | This is specialist reproductive-endocrinology research, not routine TRT-adjunct fertility preservation, hCG-equivalence, or intermittent clinic scheduling. | Limited-human |
| Historical diagnostic gonadorelin paper | Women with normal cycles and patients with secondary amenorrhea in diagnostic testing context | PubMed diagnostic paper | Historical diagnostic use | Supports gonadorelin as a historical endocrine stimulation-test agent connected to gonadotropin release. | Diagnostic response testing answers a short endocrine-response question, not chronic treatment benefit, product quality, or online schedule claims. | Moderate |
| Current DailyMed animal-label signal | Current U.S. label-visibility check | DailyMed search and animal-drug label review | Veterinary product | Current DailyMed visibility points to animal-drug labels, including cattle-only Factrel labeling. | Veterinary labels are not human efficacy, human safety, human dosing, or human product availability. | Regulatory context |
Cautions
Safety and unknowns
- Gonadorelin changes LH and FSH signaling, so endocrine diagnosis and monitoring matter. A schedule that makes sense in GnRH deficiency may not make sense for a different hormone problem.
- Pump-based specialist studies involve device burden and local skin issues; male CHH pump studies report erythema, local discomfort, bandage reactions, and practical device problems.
- Female fertility use can involve ovarian response, multiple pregnancy risk, and ovarian hyperstimulation concerns, even when pulsatile GnRH may be lower-risk than exogenous gonadotropins in some settings.
- Clinic and forum TRT-adjunct use remains thinly documented because intermittent clinic injection schedules do not mirror the pulse timing used in the core studies.
- Current U.S. animal-drug labels do not create human safety assumptions.
- Research-use or compounded products raise identity, sterility, endotoxin, concentration, storage, reconstitution, and chain-of-custody questions.
Product quality
A vial label is only a starting point
Gonadorelin is an injectable peptide topic in much of the online market, so a purity number is only one part of product quality. The practical quality question includes identity, salt form, concentration, sterility, endotoxin, degradation, storage, shipping, and lot traceability.
Vendor listings may show 2 mg or 5 mg vial sizes, HPLC-MS or purity claims, and COAs. Those are commercial documents; they cannot show that a shipped vial is a finished human-use drug.
Current DailyMed animal labels and historical human product records do not verify clinic-market, compounded, or research-use products.
Identity and salt form
Gonadorelin acetate, gonadorelin hydrochloride, veterinary labels, and research-use vials can appear under similar names while representing different product contexts.
Sterility and endotoxin
A purity number cannot show that an injectable product is sterile or endotoxin-controlled.
Concentration and dose math
Microgram pump pulses, milligram vial labels, and clinic injection schedules can be easy to confuse if concentration and reconstitution are not documented clearly.
Storage and stability
Peptide identity at manufacture cannot show stability after shipping, storage, reconstitution, or repeated handling.
Mechanism
How it is proposed to work
Gonadorelin supplies a GnRH signal. Short pulses tell the pituitary to release LH and FSH, which then act downstream on the ovaries or testes.
Pulse timing is central. Natural GnRH is secreted in pulses, and the core fertility literature often uses pump delivery to imitate that rhythm.
The same mechanism explains why gonadorelin can be relevant to ovulation, spermatogenesis, puberty induction, and diagnostic testing in selected endocrine settings.
Long-acting GnRH agonists, hCG, GHRH analogs, and ghrelin-pathway GH secretagogues are different pharmacology conversations, even when online peptide marketing groups them together.
It stimulates pituitary LH and FSH release only when delivered in pulses, because continuous exposure downregulates its own receptor: the entire basis of the pulsatile-use argument.
FAQ
Common questions
Is gonadorelin a current public fertility or hormone peptide?
No. The evidence is historical and specialist endocrine context. Current DailyMed search results are animal-drug labels, separate from fertility optimization, hormone optimization, wellness, or unsupervised-use claims.
Why mention cattle-only labels?
Because current U.S. DailyMed label visibility for gonadorelin is veterinary. Cattle labels are not human efficacy, safety, availability, or use evidence.
Is there a fertility, hormone, or pump regimen?
Registry and historical-product records show where gonadorelin has been studied, not a practical route, timing, device, or product-quality answer for public use.
Details
Technical details
Sources
References
- 1.
FDA. Orphan Drug Designations and Approvals: Lutrepulse (gonadorelin acetate) 1989.
Accessed 2026-06-09.
FDA orphan-drug record for Lutrepulse, gonadorelin acetate, with 1987 designation and 1989 marketing approval for induction of ovulation in women with hypothalamic amenorrhea due to endogenous GnRH deficiency or pulse-pattern absence.
- 2.
DailyMed. DailyMed search results for gonadorelin 2026.
Accessed 2026-06-09.
DailyMed search returned five gonadorelin labels, all marked as animal drugs: Cystorelin, Factrel, Fertagyl, GONAbreed, and OvaCyst.
- 3.
DailyMed. FACTREL- gonadorelin hydrochloride injection 2022.
Accessed 2026-06-09.
Current Factrel label is a prescription animal-drug label approved under NADA 139-237, for use in cattle only, and not for human use; it also describes gonadorelin as endogenous GnRH with the same amino acid sequence.
- 4.
ClinicalTrials.gov. LutrePulse Hypogonadotropic Hypogonadism 2026.
NCT01976728 Accessed 2026-06-09.
Completed phase 3 registry record in women with primary amenorrhea with hypogonadotropic hypogonadism; useful only as specialist reproductive-endocrinology context, not public use guidance.
- 5.
ClinicalTrials.gov. Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism 2026.
NCT02310074 Accessed 2026-06-09.
Registry record with unknown overall status comparing specialist GnRH intervention with gonadotropin therapy in male idiopathic hypogonadotropic hypogonadism.
- 6.
PubMed. Clinical use of Gonadorelin as a diagnostic agent in one- and two-step tests 1986.
PMID:3103350 Accessed 2026-06-09.
Historical human diagnostic-literature source for gonadorelin response testing; useful for specialist diagnostic context, not wellness or treatment claims.
- 7.
Other. PubChem Compound Summary for Gonadorelin 2026.
Accessed 2026-06-09.
PubChem source for CID 638793, molecular formula C55H75N17O13, and molecular weight 1182.3 g/mol.